Literature DB >> 20056810

Selectively targeting mutant BRAF in thyroid cancer.

Douglas W Ball.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20056810      PMCID： PMC2805482          DOI： 10.1210/jc.2009-2332

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  12 in total

1.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

Authors:  Rossella Elisei; Clara Ugolini; David Viola; Cristiana Lupi; Agnese Biagini; Riccardo Giannini; Cristina Romei; Paolo Miccoli; Aldo Pinchera; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

2.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

4.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Authors:  Mingzhao Xing; William H Westra; Ralph P Tufano; Yoram Cohen; Eli Rosenbaum; Kerry J Rhoden; Kathryn A Carson; Vasily Vasko; Alexandr Larin; Giovanni Tallini; Sara Tolaney; Elizabeth H Holt; Pei Hui; Christopher B Umbricht; Shehzad Basaria; Marge Ewertz; Anthony P Tufaro; Joseph A Califano; Matthew D Ringel; Martha A Zeiger; David Sidransky; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2005-09-20       Impact factor: 5.958

5.  Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation.

Authors:  B Baumann; C K Weber; J Troppmair; S Whiteside; A Israel; U R Rapp; T Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

6.  Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

Authors:  Douglas W Ball; Ning Jin; D Marc Rosen; Alan Dackiw; David Sidransky; Mingzhao Xing; Barry D Nelkin
Journal:  J Clin Endocrinol Metab       Date:  2007-09-18       Impact factor: 5.958

7.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors:  Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

8.  Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

Authors:  Paolo Salerno; Valentina De Falco; Anna Tamburrino; Tito Claudio Nappi; Giancarlo Vecchio; Rebecca E Schweppe; Gideon Bollag; Massimo Santoro; Giuliana Salvatore
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

9.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.

Authors:  C Durante; E Puxeddu; E Ferretti; R Morisi; S Moretti; R Bruno; F Barbi; N Avenia; A Scipioni; A Verrienti; E Tosi; A Cavaliere; A Gulino; S Filetti; D Russo
Journal:  J Clin Endocrinol Metab       Date:  2007-05-08       Impact factor: 5.958

10.  BRAF mutation in papillary thyroid carcinoma.

Authors:  Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506
View more
  8 in total

1.  Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.

Authors:  Ning Jin; Tianyun Jiang; David M Rosen; Barry D Nelkin; Douglas W Ball
Journal:  Clin Cancer Res       Date:  2011-08-10       Impact factor: 12.531

2.  A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Authors:  Claudia Martinuzzi; Lorenza Pastorino; Virginia Andreotti; Anna Garuti; Michele Minuto; Roberto Fiocca; Giovanna Bianchi-Scarrà; Paola Ghiorzo; Federica Grillo; Luca Mastracci
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

3.  The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas.

Authors:  Christopher Kim; Xiaofeng Bi; Dongsheng Pan; Yingtai Chen; Tobias Carling; Shuangge Ma; Robert Udelsman; Yawei Zhang
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

4.  The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.

Authors:  Bülent Kurt; Serap Yalçın; Engin Alagöz; Yıldırım Karslıoğlu; Nuri Yigit; Armağan Günal; M Salih Deveci
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

5.  Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?

Authors:  Luis Mauricio Hurtado-López; Fernando Fernández-Ramírez; Eva Martínez-Peñafiel; José Damián Carrillo Ruiz; Norma Estela Herrera González
Journal:  Med Sci Monit       Date:  2015-06-16

6.  Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

Authors:  Guoping He; Baojian Zhao; Xu Zhang; Rixiang Gong
Journal:  Oncol Lett       Date:  2013-11-29       Impact factor: 2.967

7.  Vitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032.

Authors:  Xi Su; Peng Li; Bin Han; Hao Jia; Qingzhuang Liang; Haichao Wang; Mengwei Gu; Jiaxuan Cai; Shaolei Li; Yaqi Zhou; Xin Yi; Wei Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-01-19

Review 8.  Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: two case reports and review of the literature.

Authors:  Jasmine S Sukumar; Senthil Sukumar; Darshana Purohit; Brian J Welch; Jyoti Balani; Shirley Yan; Sumitha S Hathiramani
Journal:  J Med Case Rep       Date:  2019-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.